Mason W. Freeman

Mason W. Freeman

Hoofd Techniek/Wetenschap/O&O bij CINCOR PHARMA, INC.
75 jaar
Health Technology
Consumer Services
Health Services

Profiel

Mason W.
Freeman
is currently the Director of Translational Medicine at The General Hospital Corp.
He is also a Venture Partner at 5AM Venture Management LLC and a Professor at Harvard Medical School.
Additionally, he holds the position of Chief Medical Officer at CinCor Pharma, Inc. starting in 2022.
In his former roles, Dr. Freeman served as a Director at Envoy Therapeutics, Inc. and Mitobridge, Inc. He was also a Director at scPharmaceuticals, Inc. from 2018 to 2020 and an Independent Director at Crinetics Pharmaceuticals, Inc. from 2015 to 2019.
Prior to that, he was the Head of Translational Medicine at Novartis AG from 2005 to 2007.
Dr. Freeman completed his undergraduate studies at Harvard University and obtained a doctorate degree from the University of California.

Actieve functies van Mason W. Freeman

BedrijvenFunctieBegin
CINCOR PHARMA, INC. Hoofd Techniek/Wetenschap/O&O 01-03-2022
Corporate Officer/Principal -
Corporate Officer/Principal -
Private Equity Investor 01-01-2008

Eerdere bekende functies van Mason W. Freeman

BedrijvenFunctieEinde
SCPHARMACEUTICALS INC. Directeur/Bestuurslid 01-12-2020
CRINETICS PHARMACEUTICALS, INC. Directeur/Bestuurslid 01-07-2019
Directeur/Bestuurslid 01-01-2018
NOVARTIS AG Corporate Officer/Principal 01-04-2007
Directeur/Bestuurslid -
Ervaring van Mason W. Freeman in detail bekijken

Opleiding van Mason W. Freeman

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

78

Eerstegraads connecties

11

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit11

Health Technology

Consumer Services

Health Services

Finance

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Mason W. Freeman
-40 %: de beste tools exclusief voor abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU